NEWAMSTERDAM PHARMA COMPANY's ticker is and the CUSIP is N62509117. A total of 21 filers reported holding NEWAMSTERDAM PHARMA COMPANY in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $4,362,904 | -21.0% | 500,333 | 0.0% | 0.20% | -12.4% |
| Q1 2024 | $5,523,676 | +252.7% | 500,333 | 0.0% | 0.23% | +177.4% |
| Q4 2023 | $1,566,042 | +64.7% | 500,333 | 0.0% | 0.08% | +33.3% |
| Q3 2023 | $950,633 | -9.1% | 500,333 | 0.0% | 0.06% | +1.6% |
| Q2 2023 | $1,045,696 | +13.6% | 500,333 | 0.0% | 0.06% | -7.5% |
| Q1 2023 | $920,613 | +112.0% | 500,333 | 0.0% | 0.07% | +148.1% |
| Q4 2022 | $434,289 | – | 500,333 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 21,333 | $17,795 | 0.04% |
| Exos TFP Holdings LLC | 137,317 | $119,233 | 0.03% |
| Frazier Life Sciences Management, L.P. | 500,333 | $434,289 | 0.03% |
| EcoR1 Capital, LLC | 66,665 | $726,649 | 0.02% |
| Alyeska Investment Group, L.P. | 285,105 | $1,892,000 | 0.02% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 705,352 | $564 | 0.02% |
| Bain Capital Life Sciences Investors, LLC | 100,000 | $86 | 0.01% |
| RA Capital Management | 333,333 | $289,433 | 0.01% |
| Castle Creek Arbitrage, LLC | 51,520 | $42,978 | 0.00% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 92,787 | $80,567 | 0.00% |